<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01855230</url>
  </required_header>
  <id_info>
    <org_study_id>ASM-024/II/STA-04</org_study_id>
    <nct_id>NCT01855230</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Two-Way Crossover Study to Evaluate the Safety, Tolerability and Clinical Activity of ASM-024 Administered by Dry Power Inhalation to Patients With GOLD 2 (Moderate) or GOLD 3 (Severe) Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asmacure Ltée</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asmacure Ltée</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and clinical activity of&#xD;
      ASM-024 administered as a dry powder for inhalation formulation to patients with GOLD 2 or&#xD;
      GOLD 3 COPD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, randomized, double-blind, placebo-controlled, two-way crossover study to&#xD;
      evaluate the safety, tolerability, and clinical activity of a new, dry powder for inhalation&#xD;
      formulation of ASM-024 administered twice daily for 14 days to patients with GOLD-2 or GOLD-3&#xD;
      COPD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV₁ AUC (0 -6 h)</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Residual Volume (RV)</measure>
    <time_frame>Days 1, 2, 3, &amp; 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak change in FEV₁</measure>
    <time_frame>Days 1, 2, 3, &amp; 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Inspiratory Capacity (IC)</measure>
    <time_frame>Days 1, 2, 3, &amp; 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Functional Residual Capacity (FRC)</measure>
    <time_frame>Days 1, 2, 3, &amp;14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FEV₁</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FEV₁/FVC</measure>
    <time_frame>Days 1, 2, 3, &amp; 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC (0-6 h)</measure>
    <time_frame>Days 1, 2, 3, &amp; 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication</measure>
    <time_frame>From Day 1 to Day 14</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Physical examination: Day 14; vital signs: Days 1, 2, 3, &amp; 14; 12-lead ECG: Days 1, 2, 3, &amp; 14; AEs: from Day 1 to patient's final study visit; clinical laboratory evaluations: Day 14</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>ASM-024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dry Powder for Inhalation, b.i.d., 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dry Powder for Inhalation, b.i.d., 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASM-024</intervention_name>
    <description>ASM-024 b.i.d for 14 days</description>
    <arm_group_label>ASM-024</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo b.i.d. for 14 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female adult aged over 40 yrs with a clinically confirmed diagnosis of COPD at&#xD;
             the severity stages of GOLD 2 (moderate) or 3 (severe);&#xD;
&#xD;
          -  Stable COPD for 1 month prior to screening&#xD;
&#xD;
          -  Stable smoker for at least three months prior to screening, or non-smoker, with a&#xD;
             smoking history of ≥ 10 packs years;&#xD;
&#xD;
          -  FEV₁ ≥ 30 % and &lt; 70 % of the predicted normal value;&#xD;
&#xD;
          -  Normal 12-lead ECG&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant illness except COPD or surgery within 8 weeks prior to first&#xD;
             administration of the study medication;&#xD;
&#xD;
          -  Significant medical history that, in the Investigator's opinion, may adversely affect&#xD;
             participation;&#xD;
&#xD;
          -  History of allergy or significant adverse reaction to drugs similar to ASM-024, to&#xD;
             nicotine, or to cholinergic drugs or any drugs with a similar chemical structure;&#xD;
&#xD;
          -  History of hypersensitivity (anaphylaxis, angioedema) to any drug;&#xD;
&#xD;
          -  Positive pregnancy test for female subjects;&#xD;
&#xD;
          -  Use of medications known to prolong QT/QTc interval;&#xD;
&#xD;
          -  Clinically significant 12 lead ECG at screening;&#xD;
&#xD;
          -  Clinically significant physical examination or laboratory findings or abnormal vital&#xD;
             signs;&#xD;
&#xD;
          -  History of alcohol or drug abuse;&#xD;
&#xD;
          -  Positive hepatitis B or C or HIV test at Screening;&#xD;
&#xD;
          -  Investigational drug within 30 days of Screening; long-acting investigational drug&#xD;
             within 90 days of screening;&#xD;
&#xD;
          -  Previous exposure to ASM-024; and&#xD;
&#xD;
          -  Women of child-bearing potential and male participants unwilling or unable to use&#xD;
             accepted methods of birth control.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yvon Cormier, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Asmacure Ltée</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>May 10, 2013</study_first_submitted>
  <study_first_submitted_qc>May 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2013</study_first_posted>
  <last_update_submitted>December 15, 2014</last_update_submitted>
  <last_update_submitted_qc>December 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

